PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 106

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis to 2022″. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The anticipated main drivers of market growth during the forecast period include an increased awareness of the disease and the country’s tendency to treat HCV once it is diagnosed.

Standard interferon drugs are the current market leader in China. GlobalData’s primary research revealed that Merck’s Intron A (interferon alfa-2b) is the most commonly prescribed standard interferon in China, but that Roferon-A (interferon alfa-2a) and Kadmon’s Infergen (interferon alfacon-1) are also used frequently. Standard interferon requires more-frequent dosing than peginterferon alpha, but standard interferon has been able to retain its market share in China in the face of competition from peginterferon due to its lower cost.

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting China HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in China

PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 16
3.2 Symptoms 16

4 Disease Management 17
4.1 Diagnosis and Referral Overview 17
4.2 Treatment Overview 18
4.3 China 21
4.3.1 Diagnosis 21
4.3.2 Clinical Practice 21

5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 22
5.3 Product Profiles - Major Brands 24
5.3.1 Incivek (telaprevir) 24
5.3.2 Pegasys (peginterferon alfa-2a) 29
5.3.3 PegIntron (peginterferon alfa-2b) 34
5.3.4 Copegus, Rebetol, and Generic Ribavirin 38
5.3.5 Therapeutic Class: Interferon 41

6 Opportunity and Unmet Need 42
6.1 Overview 42
6.2 Unmet Needs 43
6.2.1 Unmet Need: Treatment Tolerability 43
6.2.2 Unmet Need: Efficacy 43
6.2.3 Unmet Need: Disease Awareness 44
6.2.4 Unmet Need: Treatment Cost 45
6.2.5 Unmet Need: Shorter Treatment Duration 45
6.2.6 Unmet Need: Simplified Treatment Regimens 46
6.3 Unmet Needs Gap Analysis 47
6.4 Opportunities 48
6.4.1 Opportunity: Pan-genotypic HCV Regimen 48
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 48
6.4.3 Opportunity: Involvement of Immune System 49

7 Pipeline Assessment 50
7.1 Overview 50
7.2 Promising Drugs in Clinical Development 51
7.2.1 Simeprevir 53
7.2.2 Faldaprevir and Faldaprevir plus BI 207127 61
7.2.3 Daclatasvir and Daclatasvir plus Asunaprevir 69
7.2.4 Other Drug Classes 77

8 Market Outlook 80
8.1 China 80
8.1.1 Forecast 80
8.1.2 Key Events 84
8.1.3 Drivers and Barriers 84

9 Appendix 86
9.1 Bibliography 86
9.2 Abbreviations 94
9.3 Methodology 96
9.4 Forecasting Methodology 96
9.4.1 Percent Drug-Treated Patients 96
9.4.2 Patient Warehousing 97
9.4.3 Drugs Included in Each Therapeutic Class 97
9.4.4 General Pricing Assumptions 97
9.4.5 Individual Drug Assumptions 98
9.4.6 Generic Erosion 100
9.4.7 Selection of Pipeline Agents 100
9.4.8 Pricing of Pipeline Agents 100
9.5 Physicians and Specialists Included in this Study 102
9.6 Survey of Prescribing Physicians 104
9.7 About the Authors 105
9.7.1 Author 105
9.7.2 Global Head of Healthcare 105
9.8 About GlobalData 106
9.9 Contact Us 106
9.10 Disclaimer 106

List Of Tables

Table 1: Modes of HCV Transmission 15
Table 2: Symptoms of Acute and Chronic HCV Infection 16
Table 3: HCV Genotypes Present in the 9MM 18
Table 4: General Standard of Care by HCV Genotype 18
Table 5: Treatment Guidelines for HCV by Country 20
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 20
Table 7: Leading Treatments for HCV, 2012 23
Table 8: Product Profile - Incivek 25
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 25
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 26
Table 11: Common Incivek Adverse Drug Reactions 27
Table 12: Incivek SWOT Analysis, 2012 28
Table 13: Product Profile - Pegasys 30
Table 14: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 31
Table 15: Pegasys SWOT Analysis, 2012 33
Table 16: Product Profile - PegIntron 35
Table 17: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 35
Table 18: PegIntron SWOT Analysis, 2012 37
Table 19: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 39
Table 20: Ribavirin SWOT Analysis, 2012 40
Table 21: Summary of Minor Therapeutic Classes, 2012 41
Table 22: Overall Unmet Needs - Current Level of Attainment 42
Table 23: Clinical Unmet Needs - Gap Analysis, 2012 47
Table 24: HCV - Pipeline, 2012 51
Table 25: Comparison of Therapeutic Classes in Development for HCV, 2012 52
Table 26: Janssen's Simeprevir Ongoing Clinical Trials of Interest 54
Table 27: Product Profile - Simeprevir 55
Table 28: PILLAR Clinical Trial Results 55
Table 29: Adverse Events Observed in PILLAR Clinical Trial 56
Table 30: Simeprevir SWOT Analysis, 2012 60
Table 31: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 62
Table 32: Product Profile - Faldaprevir 63
Table 33: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 63
Table 34: Faldaprevir SWOT Analysis, 2012 68
Table 35: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 70
Table 36: Product Profile - Daclatasvir 71
Table 37: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 71
Table 38: Daclatasvir and Asunaprevir Quad Therapy Efficacy 72
Table 39: Daclatasvir Triple Therapy Adverse Events 73
Table 40: Daclatasvir SWOT Analysis, 2012 76
Table 41: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 77
Table 42: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 78
Table 43: Sales Forecasts ($m) for HCV in China, 2012-2022 82
Table 44: Key Events Impacting Sales for HCV in China, 2012 84
Table 45: Chinese HCV Market - Drivers and Barriers, 2012 84
Table 46: Physicians Surveyed, By Country 104

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 12
Figure 2: HCV Lifecycle Overview 13
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 51
Figure 4: Sales for HCV Therapeutics in China by Drug Class, 2012-2022 83

  • Global Cystic Fibrosis Market Propelled by Technological Advancement
    With increasing prevalence of cystic fibrosis and its growing awareness among people, the global market for cystic fibrosis is expected to grow at a steady pace. Cystic fibrosis is a genetic condition where the lungs and digestive system becomes clogged with excess mucus. This condition is more common among Caucasian population than people of Asian [...]
  • Bright Prospects Ahead for the SONAR Systems and Technology Market
    With advancement of technology, the global SONAR systems and technology market is increasing at a rapid pace. SONAR which is an acronym for SOund Navigation And Ranging is a technique that uses sound propagation to navigate and communicate with objects on or under the surface of the water, such as other vessels. In 2014, the [...]
  • Increase in Surgical Procedures Propelling the Anesthesia Drugs Market
    With increase in surgical operations and invasive medical tests, the market for anesthesia drugs has been growing at a steady pace. Anesthesia drugs can be broadly categorized into two types – general anesthesia drugs and local anesthesia drugs. Anesthetic drugs help in inducing sleep and preventing discomfort and pain during surgical procedures. By 2018, the [...]
  • Water Treatment Chemicals Market to be driven by Increasing Demand from Developing Economies
    The global market for water treatment chemicals is growing at a steady pace with rapid urbanization and high demand from end-users. Water treatment chemicals are used for treating municipal water as well as agricultural wastewater. With higher demand for clean, drinking water with increasing population and increase in the number of industries, the global market [...]
  • Rise in Prevalence of Allergic Diseases Driving the Global Allergy Diagnostics Market
    With rise in the incidences of allergic diseases in the world, the global allergy diagnostics market has also witnessed steady growth. In recent years, there has been an increase in the number of people suffering from different allergies, particularly food allergies and drug allergies. The number of people suffering from asthma has also increased in [...]
  • To bring in Photography to the Real World Visual Supply Co Acquires Artifact Uprising
  • Visual Supply Co, VSCO has brought a Denver-based startup, Artifact Uprising, which is focused on bringing photographers’ work from the digital hubs on regular basis by modern creatives to the real world as prints and tangible books. Artifact Uprising is …

  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Metastatic Pancreatic Cancer – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and ......
  • Microscopic Polyangiitis (MPA) – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015', provides an overview of the Microscopic Polyangiitis (MPA)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ......
  • Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H1 2015', provides an overview of the Paraganglioma (Glomus Jugulare Tumor)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest upda......
  • Trauma – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Trauma - Pipeline Review, H1 2015', provides an overview of the Trauma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Trauma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therap......
  • Brain Cancer – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Brain Cancer - Pipeline Review, H1 2015', provides an overview of the Brain Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players invo......
  • Thrombocythaemia Myelofibrosis – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2015', provides an overview of the Thrombocythaemia Myelofibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ......
  • Follicular Thyroid Cancer – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Follicular Thyroid Cancer - Pipeline Review, H1 2015', provides an overview of the Follicular Thyroid Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press rel......
  • Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ......
  • Dementia – Pipeline Review, H1 2015
    Published: 23-Jan-2015        Price: US $2000 Onwards        
    Global Markets Direct's, ‘Dementia - Pipeline Review, H1 2015', provides an overview of the Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs